March of Dimes
This article was originally published in The Tan Sheet
Executive Summary
Lovastatin should not be switched over the counter "until there are more data on its safety in pregnancy," according to March of Dimes Medical Director Nancy Green, MD. Green notes that "some published data suggest lovastatin may be teratogenic," and that "widespread public recognition of statins may increase the likelihood of statin use during pregnancy." The FDA advisory panels discussed the pregnancy issue during their Jan. 13-14 meeting...
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.